Mirtazapin Hexal (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Hexal, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is prescribed for major depressive disorder in adult patients.

GNH USA supplies Mirtazapin Hexal as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is indicated for depressive disorders that involve dysregulation of noradrenergic and serotonergic pathways.

- Major depressive disorder: reduces depressive symptoms and improves mood in adult patients. - Depression with prominent insomnia: helps restore sleep quality while treating mood symptoms. - Depression with anxiety features: alleviates both depressive and anxiety symptoms in the same therapeutic regimen.

Mirtazapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness or light‑headedness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Life‑threatening hypersensitivity reactions - Serotonin syndrome when combined with other serotonergic agents - Suicidal ideation, especially early in treatment - Hepatic dysfunction or jaundice - Severe rash or Stevens‑Johnson syndrome

When prescribing or dispensing Mirtazapine, consider the following safety measures.

- Assess hepatic function: adjust use in patients with liver impairment. - Monitor mood changes: watch for worsening depression or emergence of suicidal thoughts. - Use caution in cardiovascular disease: may cause orthostatic hypotension. - Avoid abrupt discontinuation: taper to reduce withdrawal symptoms. - Evaluate for hypersensitivity: discontinue if severe allergic reaction occurs. - Store at room temperature: keep in the original pack, protect from moisture.

Mirtazapine can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): increase serotonin toxicity. - Central nervous system depressants (e.g., benzodiazepines, alcohol): enhanced sedation. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): raise mirtazapine plasma levels. - Alcohol: may intensify sedative effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors or inducers: may alter drug concentration. - Antihypertensive agents: additive blood‑pressure lowering. - Anticholinergic drugs: increase anticholinergic burden. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened risk of gastrointestinal bleeding. - Lithium: monitor for neurotoxicity when combined.